Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023 When Administered Orally to Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Oct 2018
Price :
$35
*
At a glance
- Drugs SXC-2023 (Primary)
- Indications Psychiatric disorders
- Focus Adverse reactions
- Sponsors Promentis Pharmaceuticals
- 15 Oct 2018 Status changed from recruiting to completed.
- 04 Jun 2018 New trial record